Human peripheral blood mononuclear cells were stimulated with 10 μg/ml phytohemagglutinin (PHA) and stained with either APC Mouse IgG1, κ Isotype Control (Left panel) or SDT APC Mouse Anti-Human CD134 Antibody (Right) panel at 5μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
Host | Mouse |
Antigen | CD134 |
Synonyms | Tumor necrosis factor receptor superfamily member 4; ACT35 antigen; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; TXGP1L; TNFRSF4 |
Location | Membrane |
Accession | P43489 |
Clone Number | S-R589 |
Antibody Type | Mouse mAb |
Isotype | IgG1,k |
Application | FCM |
Reactivity | Hu |
Positive Sample | Human peripheral blood mononuclear cells |
Purification | Protein G |
Concentration | 0.2 mg/ml |
Conjugation | APC |
Physical Appearance | Liquid |
Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
application | dilution | species |
FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD134, also known as OX40 or TNFRSF4, is a co-stimulatory molecule belonging to the tumor necrosis factor receptor superfamily. It is primarily expressed on activated CD4+ and CD8+ T cells, as well as other immune cells like natural killer (NK) cells and dendritic cells. CD134 plays a crucial role in enhancing T-cell proliferation, cytokine production, and survival by interacting with its ligand, CD134L (OX40L), which is mainly expressed on antigen-presenting cells (APCs) such as dendritic cells and macrophages. This interaction promotes T-cell-mediated immune responses and helps maintain memory T cells, making CD134 an important target for immunotherapy. In cancer treatment, agonistic antibodies targeting CD134 have been shown to enhance anti-tumor immunity by boosting T-cell activity and overcoming immune suppression.
Picture
Picture
FC
